Citius Oncology partners with EVERSANA for LYMPHIR launch

From supporting FDA accelerated approval to rescuing a global Phase III trial—Catalyst Oncology delivers under pressure. Watch how we turn challenges into milestones: https://lnkd.in/eh6GYAuc #OvarianCancerAwarenessMonth2025 #OvarianCancerResearch #LatePhaseOncologyExpertise #AccelerateApproval

Healthy volunteer clinical studies can expedite oncology drug development and bring advanced, novel treatments to patients faster. Learn how Celerion supports early-stage clinical trials for oncology drugs: https://lnkd.in/d55-bsi  #BreastCancerAwareness #OncologyResearch #ClinicalTrials #InnovativeTreatments #FightBreastCancer

ICYMI, the FDA approved a new oral therapy for people living with ER+, HER2–, ESR1m #MetastaticBreastCancer. Jake Van Naarden, Executive Vice President and President of Lilly Oncology, shared his perspective on what this milestone means for patients living with #MetastaticBreastCancer. Read more: https://e.lilly/42xYxav

At TegMine Therapeutics, Inc., we’re redefining precision oncology. Today, we announced a new collaboration with #BoehringerIngelheim to develop highly selective #ADCs using our proprietary 2-Factor Antibody System. This partnership is a strong endorsement of our vision: to make cancer treatment safer, smarter, and more effective. Learn more here: https://lnkd.in/gDBb4rde #CancerResearch #Innovation #PrecisionOncology #Tegmine #BI

BillionToOne (YC S17) has filed for an IPO. The company develops a single-molecule NGS platform for prenatal and oncology diagnostics, with revenue nearly doubling to $126M in the first half of 2024. https://lnkd.in/gKW_htsb

SDBN Trending News: Avenzo collects another $60M for two small molecules and two ADCs licensed from China https://lnkd.in/ghJ2gW7e Avenzo Therapeutics, an early adopter of the China-to-US licensing model, has brought in another $60 million for its four investigational cancer treatments. With the Series B, the San Diego-based biotech has now raised $446 million [...]

Preclinical data at EORTC-NCI-AACR on Avacta Therapeutics’ pre|CISION enabled dual-payload peptide drug conjugate, highlighting the platform versatility & opportunities for novel combos. Full faridoxorubicin (AVA6000) Phase Ia data at #ESMO, with further data in salivary gland cancer in Q425. #AVCT https://lnkd.in/dxcu2fT 

Today the FDA approved a new oral therapy for people living with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), estrogen receptor 1-mutated (ESR1m) #MetastaticBreastCancer. Learn more about how this approval addresses an unmet need for patients and further advances our oncology portfolio: https://e.lilly/42xYxav

More momentum is building in the in vivo cell therapy space with a focus in oncology. Not only has BIG PHARMA (AbbVie, AZ, Gilead) swallowed up early companies, but the White House is also backing up the approach by providing various grants around the $40-50M range. https://lnkd.in/dEtmRCHh

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research https://lnkd.in/ej8ZHpVq Tempus AI Whitehawk Therapeutics Ryan Fukushima Dave Lennon Hanah Heintzelman > More US Life Science Business News at [LSUS] Life-Sciences-USA.com __